GLP-1 Drug Liraglutide Protects Against Sepsis by Reshaping Gut Bacteria | Research

The takeaway

Liraglutide attenuated sepsis-induced organ dysfunction in mice by modulating gut microbiota composition and associated metabolic pathways, reducing inflammation and improving survival.

Gut protection saves organs
Liraglutide protected against sepsis by reshaping gut bacteria and reducing inflammation through the gut-organ axis

What the researchers found

Liraglutide modulated gut microbiota composition in septic mice, altering associated metabolic pathways and reducing sepsis-induced organ dysfunction and inflammation.

Why it matters

Sepsis kills 11 million people annually worldwide. A widely available drug that protects through the gut-organ axis could save lives.

How the study worked

Sepsis model in mice with liraglutide treatment, gut microbiota 16S rRNA sequencing, metabolomic analysis, organ dysfunction assessment, and inflammatory marker profiling.

What this study cannot tell us

Mouse model. Human sepsis is heterogeneous. Cannot determine if microbiota changes are cause or effect of protection. Dosing optimization needed.

How to read the evidence

Preclinical sepsis model with comprehensive microbiota and metabolomic analysis. Novel concept for GLP-1 repurposing.

When this study was published

Published in 2025.

The bigger picture

This adds sepsis to the growing list of conditions where GLP-1 drugs show unexpected benefits, likely through the gut-immune-organ axis.

Questions still open

Would GLP-1 drugs help human sepsis patients?
Is the microbiota effect necessary for protection, or is it secondary?
Should ICU patients on GLP-1 drugs for diabetes be studied for sepsis outcomes?

Common questions

How could a diabetes drug treat sepsis?

Liraglutide protects the gut microbiome during sepsis, preventing the bacterial imbalance that worsens organ damage. By maintaining gut health, it reduces the inflammatory cascade that causes organ failure.

Is this being tested in patients?

Not yet for sepsis specifically. However, studying sepsis outcomes in ICU patients already on GLP-1 drugs could provide early human evidence.

Read the original research

GLP-1RA Liraglutide Attenuates Sepsis by Modulating Gut Microbiota and Associated Metabolites.

Nutrients, 18(3)

View on PubMed ↗Publisher’s paper ↗

Citation

Gong, Bing; Shi, Zhuang'e; Qi, Jialong; Wang, Fuping; Chen, Guobing; Su, Heng. (2026). GLP-1RA Liraglutide Attenuates Sepsis by Modulating Gut Microbiota and Associated Metabolites.. Nutrients, 18(3). https://doi.org/10.3390/nu18030531